We are currently facing an issue in receiving the NSE feed. Hence the stock prices are not updated. We are working on fixing this at the earliest. We regret the inconvenience caused.

SUVEN LIFE SCIENCES 2022-23 Annual Report Analysis

Mon, 17 Jul

SUVEN LIFE SCIENCES has announced its results for the year ended March 2023. Let us have a look at the detailed performance review of the company during FY22-23.

SUVEN LIFE SCIENCES Income Statement Analysis

• Operating income during the year rose 14.3% on a year-on-year (YoY) basis.
• The company's operating profit was by NA YoY during the fiscal. Operating profit margins witnessed a growth and down at 883.6% in FY23 as against 1000.8% in FY22.
• Depreciation charges increased by 48.9% and finance costs decreased by 19.7% YoY, respectively.
• Other income grew by 427.7% YoY.
• Net profit for the year declined by NA YoY.
• Net profit margins during the year grew from 1030.0% in FY22 to 873.5% in FY23.

SUVEN LIFE SCIENCES Income Statement 2022-23

No. of Mths Year Ending		12 Mar-22*	12 Mar-23*	% Change
Net Sales	Rs m	118	135	14.3%
Other income	Rs m	16	84	427.7%
Total Revenues	Rs m	134	220	63.5%
Gross profit	Rs m	-1,185	-1,196	NA
Depreciation	Rs m	44	65	48.9%
Interest	Rs m	7	5	-19.7%
Profit before tax	Rs m	-1,220	-1,183	NA
Tax	Rs m	0	0	0.0
Profit after tax	Rs m	-1,220	-1,183	NA
Gross profit margin	%	-1,000.8	-883.6
Effective tax rate	%	0.0	0.0
Net profit margin	%	-1,030.0	-873.5

RESPONSE PENDING: Your Meeting with Tanushree Banerjee Tomorrow...

SUVEN LIFE SCIENCES Balance Sheet Analysis

• The company's current liabilities during FY23 stood at Rs 1 billion as compared to Rs 1 billion in FY22, thereby witnessing an increase of 2.8%.
• Current assets rose 115% and stood at Rs 3 billion, while fixed assets rose 231% and stood at Rs 1 billion in FY23.
• Overall, the total assets and liabilities for FY23 stood at Rs 5 billion as against Rs 2 billion during FY22, thereby witnessing a growth of 139%.

SUVEN LIFE SCIENCES Balance Sheet as on March 2023

No. of Mths Year Ending		12 Mar-22*	12 Mar-23*	% Change
Networth	Rs m	961	3,753	290.4
Current Liabilities	Rs m	1,022	1,050	2.8
Long-term Debt	Rs m	0	0	0.0
Total Liabilities	Rs m	2,019	4,828	139.1
Current assets	Rs m	1,605	3,455	115.3
Fixed Assets	Rs m	414	1,373	231.4
Total Assets	Rs m	2,019	4,828	139.1

SUVEN LIFE SCIENCES Cash Flow Statement Analysis

• SUVEN LIFE SCIENCES's cash flow from operating activities (CFO) during FY23 stood at Rs -1 billion on a YoY basis.
• Cash flow from investing activities (CFI) during FY23 stood at Rs -3 billion, an improvement of 1,072.5% on a YoY basis.
• Cash flow from financial activities (CFF) during FY23 stood at Rs 4 billion, an improvement of 171% on a YoY basis.
• Overall, net cash flows for the company during FY23 stood at Rs 317 million from the Rs -41 million net cash flows seen during FY22.

SUVEN LIFE SCIENCES Cash Flow Statement 2022-23

Particulars	No. of months	12	12	% Change
	Year Ending	Mar-22	Mar-23
Cash Flow from Operating Activities	Rs m	-1,275	-1,031	-
Cash Flow from Investing Activities	Rs m	-222	-2,606	-
Cash Flow from Financing Activities	Rs m	1,457	3,955	171.5%
Net Cash Flow	Rs m	-41	317	-

Current Valuations for SUVEN LIFE SCIENCES

• The trailing twelve-month earnings per share (EPS) of the company stands at Rs -5.4, an improvement from the EPS of Rs -8.4 recorded last year.
• The price to earnings (P/E) ratio, at the current price of Rs 62.7, stands at -11.6 times its trailing twelve months earnings.
• The price to book value (P/BV) ratio at current price levels stands at 3.6 times, while the price to sales ratio stands at 101.1 times.
• The company's price to cash flow (P/CF) ratio stood at -13.5 times its end-of-year operating cash flow earnings.

Per Share Data/Valuations

No. of Mths Year Ending		12 Mar-22*	12 Mar-23*
Sales per share (Unadj.)	Rs	0.8	0.6
TTM Earnings per share	Rs	-8.4	-5.4
Diluted earnings per share	Rs	-5.6	-5.4
Price to Cash Flow	x	-15.8	-13.5
TTM P/E ratio	x	-15.3	-11.6
Price / Book Value ratio	x	14.7	4.0
Market Cap	Rs m	14,164	15,131
Dividends per share (Unadj.)	Rs	0.0	0.0

Ratio Analysis for SUVEN LIFE SCIENCES

• Solvency Ratios

Current Ratio: The company's current ratio improved and stood at 3.3x during FY23, from 1.6x during FY22. The current ratio measures the company's ability to pay short-term and long-term obligations.

Interest Coverage Ratio: The company's interest coverage ratio deteriorated and stood at -218.8x during FY23, from -181.1x during FY22. The interest coverage ratio of a company states how easily a company can pay its interest expense on outstanding debt. A higher ratio is preferable.

• Profitability Ratios

Return on Equity (ROE): The ROE for the company improved and stood at -31.5% during FY23, from -126.9% during FY23. The ROE measures the ability of a firm to generate profits from its shareholders capital in the company.

Return on Capital Employed (ROCE): The ROCE for the company improved and stood at -31.4% during FY23, from -126.2% during FY22. The ROCE measures the ability of a firm to generate profits from its total capital (shareholder capital plus debt capital) employed in the company.

Return on Assets (ROA): The ROA of the company improved and stood at -24.4% during FY23, from -60.1% during FY22. The ROA measures how efficiently the company uses its assets to generate earnings.

Key Ratio Analysis

No. of Mths Year Ending		12 Mar-22*	12 Mar-23*
Current ratio	x	1.6	3.3
Debtors’ Days	Days	400	218
Interest coverage	x	-181.1	-218.8
Debt to equity ratio	x	0.0	0.0
Return on assets	%	-60.1	-24.4
Return on equity	%	-126.9	-31.5
Return on capital employed	%	-126.2	-31.4

To see how SUVEN LIFE SCIENCES has performed over the last 5 years, please visit here.

SUVEN LIFE SCIENCES Share Price Performance

Over the last one year, SUVEN LIFE SCIENCES share price has moved down from Rs 63.3 to Rs 62.7, registering a loss of Rs 0.6 or around 0.9%.

Meanwhile, the S&P BSE HEALTHCARE Index is trading at Rs 26,443.1 (up 0.8%). Over the last one year it has moved up from 22,591.9 to 26,443.1, a gain of 3,851 points (up 17.0%).

Overall, the S&P BSE SENSEX is up 24.4% over the year.

(To know more, check out historical annual results for SUVEN LIFE SCIENCES and quarterly results for SUVEN LIFE SCIENCES)